乌司他丁联合生长抑素治疗重症急性胰腺炎的临床探讨  

Clinical Study of Ulinastatin Combined with Somatostatin in the Treatment of Severe Acute Pancreatitis

作　　者：周勇慧[1] ZHOU Yong-hui(General Surgery Department,the First Affiliated Hospital of Baotou Medical College,Baotou,Inner Mongolia,014010 China)

机构地区：[1]包头医学院第一附属医院普外二科

出　　处：《中外医疗》2019年第29期112-114,135,共3页China & Foreign Medical Treatment

摘　　要：目的 探讨乌司他丁联合生长抑素治疗重症急性胰腺炎的临床效果。方法 方便选取该院2016年6月-2017年6月期间收治的重症急性胰腺炎患者74例,根据入院的先后顺序进行分组,分为观察组和对照组,每组37例,对照组给予生长抑素治疗,观察组给予生长抑素加乌司他丁联合治疗,对比两组治疗效果。结果 观察组治疗总有效率97.30%、休克发生率27.03%、急性呼吸窘迫综合征发生率18.92%、急性肾功能衰竭发生率10.81%、尿淀粉酶恢复时间(4.1±1.2)d、血淀粉酶恢复时间(6.2±0.4)d、呼吸恢复时间(141.3±11.2)h、心率恢复时间(120.5±12.7)h、住院时间(10.6±1.8)d、腹痛消失时间(2.8±1.2)d、腹胀消失时间(5.6±1.2)d均优于对照组81.08%、51.05%、51.35%、32.43%、(6.8±1.1)d、(8.3±0.7)d、(186.6±10.1)h、(167.4±14.2)h、(13.4±2.2)d、(5.4±1.2)d、(7.8±1.2)d,对比存在差异有统计学意义(χ^2=10.580、9.540、9.140、9.640,t=10.230、13.710、18.410、15.170、6.080、9.050、7.950,P<0.05)。结论 在治疗重症急性胰腺炎患者时,应用乌司他丁联合生长抑素治疗安全有效,值得推广。Objective To dicuss the clinical effect of ulinastatin combined with somatostatin in the treatment of severe acute pancreatitis.Methods Convenient selected a total of 74 patients with severe acute pancreatitis admitted to the hospital from June 2016 to June 2017 were enrolled according to the order of admission.They were divided into observation group and control group,with 37 cases in each group.In the treatment group,the observation group was given combined treatment with somatostatin and ulinastatin to compare the therapeutic effects of the two groups.Results The total effective rate of treatment in the observation group was 97.30%,the incidence of shock was 27.03%,the incidence of acute respiratory distress syndrome was 18.92%,the incidence of acute renal failure was 10.81%,the recovery time of urinary amylase was(4.1±1.2)d,blood amylase.Recovery time(6.2±0.4)d,respiratory recovery time(141.3±11.2)h,heart rate recovery time(120.5±12.7)h,hospitalization time(10.6±1.8)d,abdominal pain disappearance time(2.8±1.2)d,laparoscopic disappearance time(5.6±1.2)d are better than the control group 81.08%,51.05%,51.35%,32.43%,(6.8±1.1)d,(8.3±0.7)d,(186.6±10.1)h,(167.4±14.2)h,(13.4±2.2)d,(5.4±1.2)d,(7.8±1.2)d,the difference was statistically significant(χ^2=10.580,9.540,9.140,9.640,t=10.230,13.710,18.410,15.170,6.080,9.050,7.950,P<0.05).Conclusion In the treatment of patients with severe acute pancreatitis,the application of ulinastatin combined with somatostatin is safe and effective and worthy of promotion.

关 键 词：重症急性胰腺炎 生长抑素 乌司他丁 安全性 治疗效果 

分 类 号：R576[医药卫生—消化系统]